Abstract
Background The purpose of this study was to develop a flexible, cost-efficient next-generation sequencing (NGS) protocol for genetic testing.
Methods Long-range polymerase chain reaction (LR PCR) amplicons of up to 20 kb in size were designed to amplify entire genomic regions for a panel (n=35) of loci associated with retinal diseases (RDs). Amplicons were pooled and sequenced by NGS. The analysis was applied to 227 probands diagnosed with RD: (A) 108 previously molecularly diagnosed, (B) 94 without previous genetic testing, (C) 25 undiagnosed after exome sequencing (ES).
Results The method was validated with 100% sensitivity on cohort A. LR PCR-based sequencing revealed likely causative variant(s) in 51% and 24% of proband from cohorts B and C, respectively. Breakpoints of 3 CNVs could be characterized. LR PCR libraries spike-in extended coverage data of ES. Read phasing confirmed compound heterozygosity in 5 probands.
Conclusion The proposed sequencing protocol provided deep coverage of the entire gene including intronic and promoter regions. Our method can be used (i) as a first-tier assay to reduce genetic testing costs, ii) to elucidate missing heritability cases, iii) to characterize breakpoints of CNVs at the nucleotide level, iv) to extend WES data to non-coding regions by spiking-in LR libraries, and v) to help with phasing of candidate variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded partly by the University of Zurich and partly by the Velux Stiftung (project #1371).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Helsinki Declaration. The approval for genetic testing in human patients was awarded to The Institute of Medical Molecular Genetics by the Federal Office of Public Health (FOPH) in Switzerland and written informed consent was obtained from all patients and family members included in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The following supplementary materials are available online; Figure S1: LR PCRs panel coverage results, Figure S2: ABCA4 deletion characterization, Figure S3: KCNV2 deletion characterization, Figure S4: RS1 deletion characterization, Figure S5: ES spike-in proof of concept, Figure S6: Read phasing, Text S1: Detailed long-range PCR sequencing protocol, Table S1: Long-range PCR primers, Table S2: Long-range PCR primers for breakpoint characterization, Table S3: Sanger sequencing primers, Table S4: Validation cohort findings, Table S5: Molecularly diagnosed No previous testing cohort findings, Table S6: Molecularly diagnosed Missing heritability cohort findings, Table S7: Rare variants found in undiagnosed cases.
